Medigene 
Welcome,         Profile    Billing    Logout  
 7 Products   20 Diseases  7 Products   6 Trials   338 News 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RhuDex (AV 1142742) / Dr Falk, Medigene
2020-001961-34: Clinical trial comparing the efficacy and safety of Rhudex granules with placebo in the treatment of the liver disease Primary Biliary Cholangitis

Ongoing
2
136
Europe
RhuDex 25 mg (31.75 mg RhuDex choline salt) granules, RhuDex 50 mg (63.5 mg RhuDex choline salt) granules, RhuDex 100 mg (127 mg RhuDex choline salt) granules, Granules
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Primary biliary cholangitis, A type of long-term liver disease in which the bile ducts in the liver become damaged., Diseases [C] - Immune System Diseases [C20]
 
 
EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Ongoing
3
218
Europe
Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion
SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd.
Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04]
 
 
Veregen (sinecatechins) / Sinphar Pharma, Medigene
2018-001730-18: Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepithelial neoplasia in HIV homosexuals males Ensayo clínico fase III, aleatorizado, unicéntrico, piloto, abierto, de grupos paralelos para valorar la eficacia y seguridad de la electrocoagulación vs sinecatequinas tópicas vs cidofovir tópico en el tratamiento de la neoplasia intraepitelial anal de alto grado, en varones que tienen sexo con hombres con infección por VIH (TreatAIN).

Not yet recruiting
3
108
Europe
Veregen, Cidofovir, Ointment, Cream, Veregen
Fundación Hospital Vall d'Hebron- Institut de Recerca, Instituto de Salud Carlos III
High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, Diseases [C] - Virus Diseases [C02]
 
 
2013-003107-19: A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.

Ongoing
2
56
Europe
Veregen 10% ointment, Veregen, Veregen
University of Birmingham, Sandwell and West Birmingham Hospitals NHS Trust, Medigene, NIHR RfPB
Vulval intraepithelial neoplasia (VIN)
 
 
NCT04597359: To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Recruiting
2
360
US, RoW
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sinecatechins, Camellia sinensis Leaf Catechins, Kunecatechins, Polyphenon E, Polyphenon E TM, Veregen
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
12/32
12/32
MDG1011 / Medigene
2018-000717-20: Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011

Not yet recruiting
2
2
Europe
MDG1011, Dispersion for infusion
Medigene AG, Medigene AG
High Risk Myeloid and Lymphoid Neopolasms, High risk blood tumors (white blood cell cancer), Diseases [C] - Cancer [C04]
 
 
NCT03503968 / 2017-000440-18: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Terminated
1/2
9
Europe
MDG1011, Investigator Choice therapy
Medigene AG
Safety, Tolerability, Feasibility, Treatment Efficacy
06/22
07/22
JWTCR001 / Medigene, Regeneron
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting
1
20
RoW
TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells
Peking University, Shanghai Ming Ju Biotechnology Co., Ltd.
Advanced Solid Tumor
12/25
12/28
MDG1015 / Medigene
EPITOME-1015-I, NCT06748872: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Not yet recruiting
1
55
US
Lymphodepletion, TCR-T cells (MDG1015)
Medigene AG
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
12/27
08/42
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RhuDex (AV 1142742) / Dr Falk, Medigene
2020-001961-34: Clinical trial comparing the efficacy and safety of Rhudex granules with placebo in the treatment of the liver disease Primary Biliary Cholangitis

Ongoing
2
136
Europe
RhuDex 25 mg (31.75 mg RhuDex choline salt) granules, RhuDex 50 mg (63.5 mg RhuDex choline salt) granules, RhuDex 100 mg (127 mg RhuDex choline salt) granules, Granules
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Primary biliary cholangitis, A type of long-term liver disease in which the bile ducts in the liver become damaged., Diseases [C] - Immune System Diseases [C20]
 
 
EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Ongoing
3
218
Europe
Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion
SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd.
Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04]
 
 
Veregen (sinecatechins) / Sinphar Pharma, Medigene
2018-001730-18: Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepithelial neoplasia in HIV homosexuals males Ensayo clínico fase III, aleatorizado, unicéntrico, piloto, abierto, de grupos paralelos para valorar la eficacia y seguridad de la electrocoagulación vs sinecatequinas tópicas vs cidofovir tópico en el tratamiento de la neoplasia intraepitelial anal de alto grado, en varones que tienen sexo con hombres con infección por VIH (TreatAIN).

Not yet recruiting
3
108
Europe
Veregen, Cidofovir, Ointment, Cream, Veregen
Fundación Hospital Vall d'Hebron- Institut de Recerca, Instituto de Salud Carlos III
High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, Diseases [C] - Virus Diseases [C02]
 
 
2013-003107-19: A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.

Ongoing
2
56
Europe
Veregen 10% ointment, Veregen, Veregen
University of Birmingham, Sandwell and West Birmingham Hospitals NHS Trust, Medigene, NIHR RfPB
Vulval intraepithelial neoplasia (VIN)
 
 
NCT04597359: To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Recruiting
2
360
US, RoW
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sinecatechins, Camellia sinensis Leaf Catechins, Kunecatechins, Polyphenon E, Polyphenon E TM, Veregen
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
12/32
12/32
MDG1011 / Medigene
2018-000717-20: Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011

Not yet recruiting
2
2
Europe
MDG1011, Dispersion for infusion
Medigene AG, Medigene AG
High Risk Myeloid and Lymphoid Neopolasms, High risk blood tumors (white blood cell cancer), Diseases [C] - Cancer [C04]
 
 
NCT03503968 / 2017-000440-18: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Terminated
1/2
9
Europe
MDG1011, Investigator Choice therapy
Medigene AG
Safety, Tolerability, Feasibility, Treatment Efficacy
06/22
07/22
JWTCR001 / Medigene, Regeneron
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting
1
20
RoW
TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells
Peking University, Shanghai Ming Ju Biotechnology Co., Ltd.
Advanced Solid Tumor
12/25
12/28
MDG1015 / Medigene
EPITOME-1015-I, NCT06748872: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Not yet recruiting
1
55
US
Lymphodepletion, TCR-T cells (MDG1015)
Medigene AG
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
12/27
08/42

Download Options